NDAORALTABLET
Approved
Jul 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
4/8 — Partial
PREMARIN (estrogens, conjugated) by Pfizer is estrogen receptor agonists [moa]. Approved for moderate to severe vasomotor symptoms due to menopause, moderate to severe vulvar, vaginal atrophy due to menopause () and 10 more indications. First approved in 2003.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PREMARIN (conjugated estrogens) is an oral estrogen receptor agonist indicated for moderate-to-severe vasomotor symptoms, vulvar/vaginal atrophy, hypoestrogenism, and postmenopausal osteoporosis. It works by binding to nuclear estrogen receptors in target tissues to restore hormone-dependent physiological functions in menopausal and hypogonadal women.
LOE Approaching
Product lifecycle is in decline with approaching loss of exclusivity, suggesting limited expansion opportunities and potential team restructuring in coming years.
Mechanism of Action
Estrogen Receptor Agonists
Worked on PREMARIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.